Please assess the completion status of the following clinical trial:

Trial Title: Stress Management for Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MS~* New Gd+ MRI brain lesion or clinically diagnosed exacerbation within the previous 12 months.~* Able to speak english.~* Age 18 or over.~* Able to give informed consent.~* Patients taking the drug glatiramer acetate must have been on the drug for at least 6 months prior to their Gd+ MRI brain lesion and/or exacerbation.~* Patients taking an interferon beta drug must have been on the drug for at least 1 month prior to their Gd+ MRI brain lesion and/or exacerbation.~* Patients not on disease modifying treatment are not planning to initiate treatment.~Exclusion Criteria:~* Meets criteria for dementia by scoring below the 5th percentile in 3 or more of 6 areas of neuropsychological functioning or as determined by study neuropsychologist.~* Severe psychiatric pathology, including schizophrenia, bipolar disorder, current alcoholism or substance abuse, or other severe psychiatric disorder for which this intervention would be inappropriate.~* Active and severe suicidal ideation.~* Endocrine or metabolic disorder.~* Currently in psychotherapy.~* Initiated antidepressant therapy within the past 4 weeks.~* Received corticosteroid treatment within the past 28 days.~* Pregnant or planning pregnancy in the next 12 months.~* Has any non-removable metal or medical device in the body for which an MRI could pose a danger.~* Has any risk factors for developing nephrogenic systemic fibrosis (NSF) or is allergic to Gadolinium.~* Currently uses a Baclofen pump.~* Has an Expanded Disability Status Scale score greater than 6.5.~* Recently begun relaxation, meditation, yoga, or similar form of disease management course within the past 3 months.~* Treatment with Chemotherapy.~* Treatment with Tysabri.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individual Stress Management (Type: EXPERIMENTAL): Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
- Wait List Control (Type: OTHER): Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete